Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Beijing Biostar Pharmaceuticals Co PB Ratio?
Beijing Biostar Pharmaceuticals CoHKSE:02563 9 PB Ratio is 1.68 as of Aug. 06, 2026, which is 13% below its 10-year median of 1.92. GuruFocus rates HKSE:02563 with a GF Score™ of 9/100. The stock has 4 warning signs investors should review. Among 1,227 Biotechnology companies, Beijing Biostar Pharmaceuticals Co ranks better than 68.05% on this metric.
HKSE:02563's PB Ratio is ranked better than 68.05% of 1227
companies
in the Biotechnology industry
Industry Median: 2.84
vs HKSE:02563: 1.68
During the past 12 months, Beijing Biostar Pharmaceuticals Co's average Book Value Per Share Growth Rate was -12.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.80% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Beijing Biostar Pharmaceuticals Co was -8.80% per year. The lowest was -8.80% per year. And the median was -8.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Beijing Biostar Pharmaceuticals Co PB Ratio Related Terms
Beijing Biostar Pharmaceuticals Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Biostar Pharmaceuticals Co PB Ratio Chart
Beijing Biostar Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
8.20
2.38
Beijing Biostar Pharmaceuticals Co Semi-Annual Data
HKSE:02563 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Beijing Biostar Pharmaceuticals Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Biostar Pharmaceuticals Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Biostar Pharmaceuticals Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Beijing Biostar Pharmaceuticals Co's PB Ratio falls into.
Beijing Biostar Pharmaceuticals Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a PB Ratio of 1.68 as of Aug. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. This is 13% below median its historical median of 1.92. Over the past decade, Beijing Biostar Pharmaceuticals Co's PB Ratio has ranged from 1.27 to 14.72. According to the industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #392 out of 1227 companies in the Biotechnology industry, placing it in the top 31.9%.
Is Beijing Biostar Pharmaceuticals Co's PB Ratio too high?
Beijing Biostar Pharmaceuticals Co's current PB Ratio of 1.68 is 13% below median its 10-year median of 1.92. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 14.72. The Biotechnology industry median PB Ratio is 2.84. Beijing Biostar Pharmaceuticals Co's value of 1.68 is 40.8% below this industry median. Based on the distribution chart, Beijing Biostar Pharmaceuticals Co ranks #392 out of 1227 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #392 out of 1227 companies for PB Ratio. This puts Beijing Biostar Pharmaceuticals Co in the upper half of its industry. The industry median PB Ratio is 2.84. Beijing Biostar Pharmaceuticals Co's value of 1.68 is 40.8% below this benchmark. Historically, Beijing Biostar Pharmaceuticals Co's own PB Ratio has ranged from 1.27 to 14.72 over the past decade. While the company's 10-year median is 1.92 vs. the industry median of 2.84, Beijing Biostar Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.84, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Biostar Pharmaceuticals Co's current PB Ratio of 1.68 is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Biostar Pharmaceuticals Co's current PB Ratio is 1.68, which is 13% below median its own 10-year median of 1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current PB Ratio of 1.68. The current PB Ratio is 1.68, which is 13% below median its 10-year median of 1.92 and 40.8% below the Biotechnology industry median of 2.84. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current PB Ratio is 1.68 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score
Get the complete analysis for HKSE:02563
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02563 has been successfully added to your 
